Article Text

Download PDFPDF

FRI0607 Long-term and optimization of infliximab in refractory uveitis associated to behÇet disease. multicentre study of 100 patients
  1. LC Domínguez Casas1,
  2. V Calvo-Río1,
  3. E Beltrán2,
  4. J S-Bursόn3,
  5. M Mesquida4,
  6. A Adán4,
  7. M Hernandez4,
  8. F L-Longo5,
  9. M H-Grafella6,
  10. E Valls7,
  11. L M-Costa8,
  12. A Sellas9,
  13. J G-Serrano10,
  14. J Callejas10,
  15. N Ortego10,
  16. J Herreras11,
  17. A Follonosa12,
  18. O Maíz13,
  19. A Blanco13,
  20. I Torre14,
  21. C F-Espartero15,
  22. V Jovani16,
  23. D Peitado17,
  24. D Díaz-Valle18,
  25. E Pato18,
  26. C F-Cid19,
  27. E Aurrecoechea20,
  28. M García21,
  29. M Caracuel22,
  30. A Atanes23,
  31. F Francisco24,
  32. S Insua25,
  33. S González-Suárez26,
  34. A S-Andrade27,
  35. L Linares28,
  36. F Romero29,
  37. A García30,
  38. R Almodovar31,
  39. E Minguez32,
  40. C Carrasco33,
  41. E Raya10,
  42. M Alcalde34,
  43. C F-Carballido35,
  44. F Pagés36,
  45. M González-Vela1,
  46. C Fernández-Díaz1,
  47. N Vegas-Revenga1,
  48. R Demetrio-Pablo1,
  49. M González-Gay1,
  50. R Blanco1
  1. 1HUMV, Santander
  2. 2H Mar, Barcelona
  3. 3H Valme, Sevilla
  4. 4H Clinic, Barcelona
  5. 5H G-Marañόn, Madrid
  6. 6H General
  7. 7H, Valencia
  8. 8H Peset, Valencis
  9. 9H Vall d'Hebron, Barcelona
  10. 10H S Cecilio, Granada
  11. 11IOBA, Valladolid
  12. 12H Cruces, Bilbao
  13. 13H, Donostia
  14. 14H Basurto, Bilbao
  15. 15H Mόstoles, Madrid
  16. 16H General, Alicante
  17. 17H Paz
  18. 18H S Carlos, Madrid
  19. 19H, Pontevedra
  20. 20H, Torrelavega
  21. 21H Princesa, Madrid
  22. 22H, Cόrdoba
  23. 23HUAC, A Coruña
  24. 24H D Negrín, Las Palmas
  25. 25H, Santiago Compostela
  26. 26H Cabueñes, Gijόn
  27. 27H L Augusti, Lugo
  28. 28H Arrixaca, Murcia
  29. 29F J Díaz
  30. 30H 12 octubre
  31. 31F Alcorcόn, Madrid
  32. 32H Clínico, Zaragoza
  33. 33H, Merida
  34. 34H S Ochoa, Madrid
  35. 35H Elda, Alicante
  36. 36H, Palencia, Spain


Objectives To assess the long term efficacy and optimization of Infliximab (IFX) in refractory Uveitis of Behçet Disease (BD)

Methods Multicentre study of Uveitis associated-BD refractory to conventional immunosupressive drug. Ocular inflammation was evaluated with “SUN criteria” (Am J Ophthalmol 2005;140:509–516) and the macular thickening with OCT. Results are expressed as mean±SD or median [IQR] (comparison, Wilcoxon test)

Results We studied 100 patients/180 affected eyes (54M/46W), mean age 40.7±10.1. The ocular pattern was panuveitis (n=62), posterior (27) and anterior uveítis (11). Before IFX they received iv MP (28), cyclosporine (75), azathioprine (56), metotrexate (43) and others (33). IFX dose ranged between 3–5mg/kg/4 or 8 weeks. In patients in remission IFX was optimized (n=28) or stopped (n=20).

Conclusions IFX is an effective long term-treatment in refractory Uveitis of BD. Optimization and even discontinuation of IFX after remission is possible.

Disclosure of Interest None declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.